# Precocious Puberty

Evaluate early pubertal signs by separating transient or isolated variants from progressive hypothalamic-pituitary-gonadal activation and gonadotropin-independent disease. Age, tempo, growth, bone maturation, gonadotropin testing, and targeted imaging determine who needs observation, etiologic investigation, or GnRH-agonist suppression.

**Clinical question:** How should clinicians distinguish benign early pubertal variants, central precocious puberty, and peripheral causes and select treatment?

Updated: 2026-09-16T00:34:45.573949+00:00

## What matters in practice
- For Tanner B2 onset at age 7.0-8.0 years, use periodic examinations rather than immediate laboratory or imaging evaluation; distinguish true glandular breast tissue from lipomastia. [17][18]
- In girls younger than 7 years with initial Tanner B2 development, observe for 4-6 months to distinguish unsustained or slowly progressive development from rapidly progressive puberty before diagnostic testing. [17][18]
- A pubertal stimulated LH response greater than 5 IU/L supports central activation; basal LH is a screening tool rather than a substitute for stimulation testing in girls. [24]
- Isolated pubic or axillary hair, body odor, or acne without breast development or genital enlargement favors premature adrenarche rather than central puberty; virilization warrants exclusion of adrenal enzymatic defects and androgen-secreting tumors. [10]
- Use GnRH-agonist therapy for confirmed central precocious puberty when suppression is selected; avoid routinely extending treatment beyond age 10-11 years in girls or 11-12 years in boys and/or the guideline bone-age ranges. [17]

## Who needs observation versus prompt endocrine evaluation?

Use age at onset, pubertal sequence, and progression rate before ordering broad testing.

Treat breast development before age 8 years in girls or testicular enlargement before age 9 years in boys as possible central precocious puberty (CPP), particularly when physical changes follow the usual isosexual pubertal sequence with accelerated linear growth and advancing skeletal maturation. CPP reflects premature hypothalamic-pituitary-gonadal activation and can advance bone age sufficiently to reduce adult-height potential. [1][6][20]

For a girl presenting with Tanner B2 breast development at age 7.0-8.0 years, perform serial physical examinations rather than immediate hormonal testing or imaging. Confirm palpable glandular tissue rather than adipose tissue in patients with overweight or obesity. A 4-6-month observation period is also appropriate for initial B2 development before age 7 years when the presentation is not clearly rapidly progressive; progression during surveillance changes the next step to diagnostic evaluation. [17][18]

Move directly from observation to evaluation when development is rapidly progressive, when growth acceleration or skeletal maturation is evident, or when findings are discordant with ordinary central puberty. Boys with sexual precocity merit careful etiologic assessment because underlying disorders are more frequent than in girls. [10][12]
- Document Tanner staging, height, and interval growth velocity at each visit; height monitoring provides the clinical trajectory needed to identify progressive activation. [2]
- Ask whether the sequence is concordant: breast development in girls or testicular enlargement in boys suggests gonadal-axis activation, whereas isolated androgenic signs indicate a separate branch. [10][20]
- Escalate promptly for clitoromegaly, phallic enlargement, voice deepening, or other virilization, which is not characteristic of uncomplicated premature adrenarche. [10]

*Clinical patterns that determine the first diagnostic branch. [10][11][12][20]*

| Pattern | Discriminating findings | Next action |
| --- | --- | --- |
| Possible progressive CPP | Breast development or testicular enlargement before traditional age thresholds, with pubertal progression, growth acceleration, or advanced bone maturation. [1][6][20] | Proceed to biochemical confirmation of hypothalamic-pituitary-gonadal activation and etiologic assessment. [24] |
| Premature thelarche | Isolated breast tissue without accelerated linear growth, rapid breast progression, or advanced skeletal maturation; often regresses over months. [11] | Serial examination; test if progression or additional pubertal findings emerge. [17][18] |
| Premature adrenarche | Gradual pubic or axillary hair, body odor, or acne without breast development, clitoral enlargement, phallic enlargement, or testicular enlargement. [10] | Evaluate for peripheral androgen excess when virilization or atypical progression is present. [10] |
| Peripheral precocious puberty | Sex-steroid effects without hypothalamic-pituitary-gonadal activation; may result from a secreting tumor or other underlying disorder. [12][21] | Direct testing and imaging toward the suspected steroid source or disease mechanism. [10][12] |

## How should gonadotropin testing establish central puberty?

Interpret laboratory data in the clinical context; a single basal LH cannot reliably exclude CPP in girls.

Use a GnRH or GnRH-agonist stimulation test when the clinical question is whether early findings represent CPP. A stimulated LH greater than 5 IU/L is a commonly used discriminator for central activation. In boys, basal LH greater than 0.3 IU/L and stimulated LH greater than 5 IU/L are distinctive; these measures perform less reliably in girls, especially at Tanner stages 2-3. [24]

Use basal LH as a screening test, not as a replacement for stimulation testing in girls with equivocal early findings. Although basal LH greater than 1.0 IU/L has reported positive predictive value of 96.4% for CPP, a basal threshold above 1.1 IU/L has limited sensitivity and specificity and should not independently exclude CPP. [24]

Do not use FSH concentration alone to distinguish CPP from early puberty in girls age 7-8 years because basal and stimulated FSH are nonconclusive. When gonadotropin responses remain low in an early-pubertal girl, correlate with clinical progression; an estradiol peak up to 50 pg/mL measured 20-24 hours after leuprolide stimulation may help identify CPP. [24]
- Order bone-age assessment when determining whether early maturation is progressing and whether compromised adult-height potential is plausible; advanced skeletal maturation is a key consequence of CPP. [1][6]
- Interpret stimulated and basal gonadotropins alongside serum sex steroids and serial examination rather than treating any isolated laboratory value as definitive. [2][24]
- After central activation is confirmed, distinguish idiopathic CPP from central nervous system-associated disease and from peripheral sex-steroid exposure or production. [11][12][21]

### When discordant findings redirect the workup

Predominant pubic hair or androgenic changes without breast development or genital enlargement should redirect the evaluation away from CPP toward premature adrenarche and peripheral androgen excess. Late-onset 21-hydroxylase deficiency and adrenal tumors are among the conditions requiring exclusion when the phenotype is atypical or virilizing. [10]

Sexual development caused by a secreting tumor can produce secondary sexual characteristics without activating the hypothalamic-pituitary-gonadal axis. A nonpubertal gonadotropin response in a child with convincing sex-steroid effects therefore requires a cause-directed peripheral evaluation rather than GnRH-agonist monotherapy. [12][21]

*Interpretation of gonadotropin testing in suspected early puberty. [24]*

| Test result | Interpretation | Decision consequence |
| --- | --- | --- |
| Stimulated LH >5 IU/L | Supports central hypothalamic-pituitary-gonadal activation. [24] | Classify as CPP in the appropriate clinical phenotype and proceed with etiologic and treatment assessment. [24] |
| Basal LH >1.0 IU/L | Has reported positive predictive value of 96.4% for CPP. [24] | May support diagnosis, but apply clinical correlation and do not use basal testing alone to exclude disease. [24] |
| Basal LH >1.1 IU/L in girls | Insufficient sensitivity and specificity to substitute for a GnRH stimulation test. [24] | Obtain stimulation testing when CPP remains clinically suspected. [24] |
| Low gonadotropin response with sex-steroid manifestations | Raises gonadotropin-independent peripheral precocious puberty. [12][21] | Investigate the underlying source of hormone production or exposure. [10][12] |

## Which etiologic pattern changes imaging and management?

Central and peripheral pathways require different imaging targets and definitive therapy.

CPP can be idiopathic, especially in girls, but may also reflect cerebral congenital malformations or acquired central nervous system insults. Once CPP is established, use the patient’s sex, age, neurologic history, tempo, and examination findings to determine the urgency and scope of central nervous system assessment. Brain imaging is part of the evaluation framework for true precocious puberty, whereas isolated benign variants do not automatically require the same workup. [11][12]

Peripheral precocious puberty is gonadotropin-independent and should be managed according to its cause rather than with CPP suppression alone. Consider hormone-secreting tumors when secondary sexual characteristics develop without central-axis activation; evaluate virilizing androgen excess for adrenal steroidogenic defects, including late-onset 21-hydroxylase deficiency, and adrenal tumors. [10][12][21]

Do not label isolated breast development as CPP unless progression establishes broader pubertal activation. Premature thelarche lacks accelerated linear growth, rapid breast progression, and advanced skeletal maturation; it commonly presents in toddlers and may regress after several months. [11]
- Use a central nervous system-focused assessment for confirmed CPP with features that raise concern for an intracranial cause, especially in boys. [11][12]
- Use an adrenal/peripheral workup for virilization or isolated androgenic signs rather than relying on pubertal staging alone. [10]
- Reassess the working diagnosis after serial examinations: slowly progressive or unsustained development may avoid unnecessary imaging and treatment. [17][18]

*Etiologic branching after early pubertal signs are identified. [10][11][12][21]*

| Axis pattern | Likely etiologic domain | Management direction |
| --- | --- | --- |
| Central activation | Idiopathic CPP or cerebral congenital/acquired pathology. [11][12] | Consider central nervous system evaluation based on clinical risk; assess candidacy for GnRH-agonist suppression. [17] |
| Gonadotropin-independent sex-steroid effects | Hormone-secreting tumor or other peripheral source. [12][21] | Identify and treat the underlying source; do not assume CPP. [10][12] |
| Isolated androgenic signs | Premature adrenarche; exclude late-onset 21-hydroxylase deficiency and adrenal tumor when phenotype is concerning. [10] | Use peripheral androgen-focused evaluation when virilization or atypical progression occurs. [10] |
| Isolated breast tissue without progression | Premature thelarche. [11] | Observe clinically and test only if progression develops. [17][18] |

## When and how should central precocious puberty be treated?

GnRH agonists suppress central-axis puberty; treatment selection should follow confirmation of CPP and assessment of progression.

GnRH agonists are indicated for pediatric patients with CPP and are used to suppress pituitary gonadotropins and peripheral sex steroids. The treatment objective is to arrest progressive pubertal advancement and mitigate accelerated bone maturation that can diminish adult height. The decision is individualized; older girls with slowly progressive puberty may not require the same testing or treatment intensity as younger or rapidly progressive patients. [1][4][17][19]

Leuprolide depot-ped is administered intramuscularly by a health care professional. Available regimens include weight-based monthly starting doses of 7.5 mg, 11.25 mg, or 15 mg; 11.25 mg or 30 mg every 3 months; and 45 mg every 6 months. Do not use partial syringes or combine syringes because formulations have different release characteristics. If pituitary gonadotropins and peripheral sex steroids remain inadequately suppressed at the maximal dose, consider another available GnRH agonist indicated for CPP. [4]

Triptorelin extended-release suspension is an alternative for patients age 2 years or older: administer 22.5 mg intramuscularly once every 24 weeks, by a health care provider. Discontinue at an age judged appropriate for physiologic pubertal onset; routine continuation beyond chronological age 10.0-11.0 years in girls or 11.0-12.0 years in boys, and/or bone age 11.0-12.0 years in girls or 12.0-13.0 years in boys, is discouraged. [2][17]
- Do not routinely add growth hormone to GnRH-agonist therapy for CPP. [17]
- Discuss seizure history, epilepsy, prior brain or cerebrovascular disease, and brain tumors before triptorelin therapy because seizures have been reported with GnRH agonists and risk may be higher in these groups. [3]
- Do not use GnRH agonist treatment as definitive therapy for gonadotropin-independent precocious puberty; treat the peripheral cause. [10][12][21]

### Expected height and pubertal recovery considerations

Height benefit depends on remaining growth potential and timing of cessation. In a long-term triptorelin cohort, predicted adult height increased from 158.2 cm at treatment start to 163.9 cm at treatment completion, with final height 161.6 cm; greater bone age at discontinuation correlated with less residual post-treatment growth. [7]

In that cohort, residual growth capacity was optimal when bone age at treatment cessation was 12-12.5 years, and menarche occurred at a median of 1.1 years after treatment discontinuation. Use these data to frame cessation discussions, while following the guideline’s age and bone-age limits rather than treating to a fixed calendar duration. [7][17]

*FDA-labeled injectable GnRH-agonist regimens for CPP. [2][4]*

| Agent | Dose and route | Key administration rule |
| --- | --- | --- |
| Leuprolide depot-ped, 1-month formulation | 7.5 mg, 11.25 mg, or 15 mg intramuscularly; starting dose is weight based. [4] | Administer by a health care professional; do not use partial or combined syringes. [4] |
| Leuprolide depot-ped, 3-month formulation | 11.25 mg or 30 mg intramuscularly every 3 months. [4] | Use the formulation-specific syringe and monitor hormonal suppression. [4] |
| Leuprolide depot-ped, 6-month formulation | 45 mg intramuscularly every 6 months. [4] | Select dosing frequency individually; discontinue at an appropriate pubertal age. [4] |
| Triptorelin extended release | 22.5 mg intramuscularly once every 24 weeks for patients age 2 years or older. [2] | Administer only by a health care provider and reassess efficacy after initiation and each subsequent dose. [2] |

## How should response, inadequate suppression, and treatment cessation be monitored?

Track clinical progression and biochemical suppression rather than relying on a random LH alone.

Monitor GnRH-agonist response with clinical pubertal progression, growth rate, and hormonal suppression. For triptorelin, assess LH after a GnRH or GnRH-agonist stimulation test, basal LH, or serum sex-steroid concentrations beginning 1-2 months after initiation, thereafter as needed to confirm efficacy, and with each subsequent dose; measure height to calculate growth rate. [2]

For leuprolide, monitor hormonal and clinical parameters to ensure adequate suppression. If suppression remains inadequate despite maximal dosing, reassess adherence and dosing formulation, confirm the biochemical pattern, and consider switching to another GnRH agonist approved for CPP rather than combining or partially dosing depot syringes. [1][4]

Plan discontinuation around anticipated physiologic pubertal timing and residual growth potential. Avoid routine treatment extension beyond the guideline age and bone-age ranges, and counsel families that pubertal maturation resumes after discontinuation; median time to menarche was 1.1 years in one long-term triptorelin cohort. [7][17]
- At each administration interval, record height and pubertal staging and ask about clinical progression that may signal inadequate suppression. [2][4]
- Use laboratory testing to resolve suspected treatment failure; random gonadotropin values can be difficult to interpret in treated children, so integrate them with clinical findings and sex-steroid concentrations. [2][6]
- Reconsider the diagnosis if the clinical course becomes discordant with CPP suppression, particularly if progressive virilization suggests an untreated peripheral androgen source. [10][12]

*Monitoring actions during GnRH-agonist treatment for CPP. [2][4][17]*

| Time point | Assessments | Action if abnormal |
| --- | --- | --- |
| 1-2 months after triptorelin initiation | LH after GnRH/GnRH-agonist stimulation, basal LH, or serum sex steroids; height for growth rate. [2] | If suppression is not maintained, reassess treatment efficacy and dosing strategy. [2][4] |
| During therapy and with each subsequent triptorelin dose | Hormonal assessment as needed, height, and clinical pubertal progression. [2] | Confirm continued suppression; investigate clinical or biochemical escape. [2][4] |
| At planned cessation | Chronologic age, bone age, and residual growth considerations. [7][17] | Avoid routine continuation beyond age 10-11 years in girls or 11-12 years in boys and/or specified bone-age ranges. [17] |

## Common questions

### Should every girl with breast development before age 8 years undergo immediate MRI and laboratory testing?

No. For Tanner B2 onset at age 7.0-8.0 years, periodic physical examinations are suggested before immediate laboratory or radiologic evaluation. For girls younger than 7 years with initial B2 development, a 4-6-month observation period can distinguish unsustained or slowly progressive findings from rapidly progressive puberty; progression triggers diagnostic evaluation. [17][18]

### Can a normal or low basal LH exclude central precocious puberty in girls?

No. Basal LH has limited sensitivity and specificity in girls and should be used as a screen rather than a substitute for GnRH stimulation testing when the clinical phenotype remains concerning. A stimulated LH greater than 5 IU/L supports central activation. [24]

## References
1. [PDF] 020263Orig1s042 | FDA — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/020263Orig1s042.pdf
2. [PDF] This label may not be the latest approved by FDA. For current ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208956s009lbl.pdf
3. [PDF] 208956Orig1s000 - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208956Orig1s000Lbl.pdf
4. [PDF] HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020263s056lbl.pdf
5. Trends in the Incidence of Central Precocious Puberty and ... — jamanetwork.com — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2771377
6. Central precocious puberty: a review of diagnosis, treatment, and outcomes — www.thelancet.com — https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(23)00237-7/abstract
7. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. | Archives of Disease in Childhood — adc.bmj.com — https://adc.bmj.com/content/75/4/292
8. Central Precocious Puberty and Gonadotropin-Releasing Hormone Treatment | Nature Research Intelligence — www.nature.com — https://www.nature.com/research-intelligence/nri-topic-summaries/central-precocious-puberty-and-gonadotropin-releasing-hormone-treatment-micro-207095
9. Reproductive risk factors across the female lifecourse and later ... — www.cell.com — https://www.cell.com/cell-metabolism/fulltext/S1550-4131(24)00002-0
10. Premature Adrenarche — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0891524507002593
11. Premature Thelarche: Age at Presentation Affects Clinical Course but Not Clinical Characteristics or Risk to Progress to Precocious Puberty — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S002234760900986X
12. Precocious Puberty - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/precocious-puberty
13. Update on Precocious Puberty in Girls - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1083318819302086
14. Adult height after gonadotropin‐releasing hormone agonist treatment in girls with early puberty: A meta‐analysis - Park - 2020 - Clinical Endocrinology - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/abs/10.1111/cen.14214
15. POSTER VIEWING SESSION - REPRODUCTIVE ENDOCRINOLOGY — academic.oup.com — https://academic.oup.com/humrep/article/26/suppl_1/i296/851934
16. JCEM THE JOURNAL OF CLINICAL ENDOCRINOLOGY ... — academic.oup.com — https://academic.oup.com/jcem/issue-pdf/110/12/65358269
17. Central Precocious Puberty - Endocrine Society — www.endocrine.org — https://www.endocrine.org/clinical-practice-guidelines/central-precocious-puberty
18. They Grow Up So Fast: Endocrine Society Releases Central Precocious Puberty Guideline - Endocrine News — endocrinenews.endocrine.org — https://endocrinenews.endocrine.org/they-grow-up-so-fast-endocrine-society-releases-central-precocious-puberty-guideline
19. Not all children with early puberty need the same level of testing or treatment | Endocrine Society — www.endocrine.org — https://www.endocrine.org/news-and-advocacy/news-room/2026/not-all-children-with-early-puberty-need-the-same-level-of-testing-or-treatment
20. ENP113: Clinical Practice Guideline on Central Precocious Puberty | Endocrine Society — www.endocrine.org — https://www.endocrine.org/podcast/enp113
21. Understanding precocious puberty in girls - Ovid — elearning.rcog.org.uk — https://elearning.rcog.org.uk/sites/default/files/Paediatric%20and%20adolescent%20gynaecology/Tirumuru_et_al-2012-The_Obstetrician_&_Gynaecologist.pdf
22. Central Precocious Puberty: A Clinical Practice Guideline Education ... — education.endocrine.org — https://education.endocrine.org/AssetListing/Precocious-Puberty-A-Clinical-Practice-Guideline-Education-Activity-2026004HG-25562/Guideline-Central-Precocious-Puberty-45722
23. Pathological and Incidental Findings on Brain MRI in a Single ... — uat.ajnr.org — https://uat.ajnr.org/lookup/external-ref?access_num=10.1371%2Fjournal.pone.0029829&link_type=DOI
24. Gonadotropin-releasing hormone stimulation test and diagnostic cutoff in precocious puberty: a mini review - PMC — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pmc/articles/7538306

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.